Congress is moving forward to reauthorize key user-fee programs that fund the FDA as part of the continuing resolution, leaving behind many policy riders negotiated this year.
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.
